Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Laroni

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Trials|May 11, 2019
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosisAntonio Uccelli, Alice Laroni, Lou Brundin, et al.
Multiple Sclerosis and Related Disorders|February 25, 2026
Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the "GA transition" studyIrene Schiavetti, Pietro Annovazzi, Cinzia Cordioli, et al.
Journal of Neurology|June 19, 2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyJessica Frau, Francesco Saccà, Alessio Signori, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 7, 2020
Impact of treatment on cellular immunophenotype in MS: A cross-sectional studyMaria Cellerino, Federico Ivaldi, Matteo Pardini, et al.
The Lancet. Neurology|October 23, 2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trialAntonio Uccelli, Alice Laroni, Rehiana Ali, et al.
Neurology|February 14, 2018
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risksEmilio Portaccio, Lucia Moiola, Vittorio Martinelli, et al.
Multiple Sclerosis and Related Disorders|July 20, 2020
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems groupMarcello Moccia, Pietro Annovazzi, Maria Chiara Buscarinu, et al.
Neurology|February 14, 2018
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risksEmilio Portaccio, Pietro Annovazzi, Angelo Ghezzi, et al.
International Journal of Medical Informatics|June 10, 2026
Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital surveyLuigi Lavorgna, Giuseppina Miele, Marta Ponzano, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Trials|May 11, 2019
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosisAntonio Uccelli, Alice Laroni, Lou Brundin, et al.
Multiple Sclerosis and Related Disorders|February 25, 2026
Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the "GA transition" studyIrene Schiavetti, Pietro Annovazzi, Cinzia Cordioli, et al.
Journal of Neurology|June 19, 2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyJessica Frau, Francesco Saccà, Alessio Signori, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 7, 2020
Impact of treatment on cellular immunophenotype in MS: A cross-sectional studyMaria Cellerino, Federico Ivaldi, Matteo Pardini, et al.
The Lancet. Neurology|October 23, 2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trialAntonio Uccelli, Alice Laroni, Rehiana Ali, et al.
Neurology|February 14, 2018
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risksEmilio Portaccio, Lucia Moiola, Vittorio Martinelli, et al.
Multiple Sclerosis and Related Disorders|July 20, 2020
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems groupMarcello Moccia, Pietro Annovazzi, Maria Chiara Buscarinu, et al.
Neurology|February 14, 2018
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risksEmilio Portaccio, Pietro Annovazzi, Angelo Ghezzi, et al.
International Journal of Medical Informatics|June 10, 2026
Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital surveyLuigi Lavorgna, Giuseppina Miele, Marta Ponzano, et al.
Pageof 8